Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (181,538)	$ (457,870)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	11,374	19,171
Amortization and impairment of internal-use software	6,296	4,374
Stock-based compensation expense	50,467	101,198
Loss (gain) on disposal of property and equipment	60	(5)
Loss on disposition of Lemonaid Health Limited	0	2,026
Impairment of long-lived assets	10,041	0
Goodwill impairment	0	198,800
Other operating activities	0	(504)
Changes in operating assets and liabilities:
Accounts receivable, net (includes related party amounts of nil and $19 for the nine months ended December 31, 2024 and 2023, respectively)	(6,749)	(16,257)
Inventories	(8,943)	(5,420)
Deferred cost of revenue	(5,128)	(6,846)
Prepaid expenses and other current assets	(980)	(4,490)
Operating lease right-of-use assets	5,565	5,341
Other assets	629	755
Accounts payable (includes related party amounts of $(3,809) and $3,879 for the nine months ended December 31, 2024 and 2023, respectively)	(2,840)	669
Accrued expenses and other current liabilities (includes related party amounts of $(4,562) and $42 for the nine months ended December 31, 2024 and 2023, respectively)	11,468	(5,906)
Deferred revenue (includes related party amounts of $(19,035) and $8,247 for the nine months ended December 31, 2024 and 2023, respectively)	(11,908)	32,948
Operating lease liabilities	(6,981)	(6,483)
Other liabilities	313	(36)
Net cash used in operating activities	(128,854)	(138,535)
Cash flows from investing activities:
Purchases of property and equipment	(714)	(850)
Proceeds from sale of property and equipment	2,475	6
Capitalized internal-use software costs	(4,730)	(6,636)
Net cash used in investing activities	(2,969)	(7,480)
Cash flows from financing activities:
Proceeds from exercise of stock options	58	687
Proceeds from issuance of common stock under employee stock purchase plan	331	1,411
Payments of deferred offering costs	(4)	(356)
Payments for taxes related to net share settlement of equity awards	(135)	(158)
Net cash provided by financing activities	250	1,584
Net decrease in cash, cash equivalents and restricted cash	(131,573)	(144,431)
Cash, cash equivalents and restricted cash—beginning of period	224,861	395,222
Cash, cash equivalents and restricted cash—end of period	93,288	250,791
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	6	213
Stock-based compensation capitalized for internal-use software costs	1,773	2,927
Reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the amounts shown in the condensed consolidated statements of cash flows above:
Cash and cash equivalents	79,350	242,418
Restricted cash, current	1,664	1,399
Restricted cash, noncurrent	12,274	6,974
Total cash, cash equivalents and restricted cash	$ 93,288	$ 250,791